Targeting BET bromodomains for cancer treatment - Wikidata - awgldk - TriplyDB

Targeting BET bromodomains for cancer treatment

Targeting BET bromodomains for cancer treatment

http://www.wikidata.org/entity/Q28263519

about

Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.The heterogeneous landscape of ALK negative ALCL.Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains Chemical probes targeting epigenetic proteins: Applications beyond oncology.Exploiting Epigenetic Alterations in Prostate Cancer.Bromodomain protein 4 is a novel predictor of survival for gastric carcinoma NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth.Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex BET Inhibition Attenuates Helicobacter pylori-Induced Inflammatory Response by Suppressing Inflammatory Gene Transcription and Enhancer Activation.Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.Nucleic acid clamp-mediated recognition and stabilization of the physiologically relevant MYC promoter G-quadruplex.Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis Chlamydia trachomatis Prevents Apoptosis Via Activation of PDPK1-MYC and Enhanced Mitochondrial Binding of Hexokinase II.Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin.Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.Epigenomic regulation of oncogenesis by chromatin remodeling.Synthesis and biological evaluation of N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)benzenesulfonamide derivatives as new BET bromodomain inhibitors for anti-hematologic malignancies activities.Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development.Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue Epigenetic balance of gene expression by Polycomb and COMPASS families.Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.The landscape of new drugs in lymphoma Medulloblastoma: Molecular Classification-Based Personal Therapeutics.Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1).Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4.Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues.Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.Epigenetic Basis of Cellular Senescence and Its Implications in Aging.Activity of bromodomain protein inhibitors/binders against asexual-stage Plasmodium falciparum parasites.The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.Recent Advances in Prostate Cancer Treatment and Drug Discovery.The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.

P2860

Q28076548-E0E94173-D827-4151-A654-17A66A89416F Q30248629-6CEC6541-9CE4-497E-9BC8-B50468597CE3 Q33567012-47FF5687-B307-4906-A0A8-35D65B7581E8 Q33725257-39EAAD40-96D6-4FA9-8DD1-99CD471AB85D Q33751386-DCE4F98C-EA47-4FD2-A586-4ED0E64BBB99 Q33755160-AF044199-C316-4B46-83B8-25CEFA1D3913 Q33761645-15CE5BA2-C0E1-46C4-BF51-2C4249E00838 Q36033498-06BAC72C-A97E-45C1-A9DB-C87455F4C47D Q36073783-550667EC-A6C8-44D1-BBA3-2ECC406C16EF Q36185007-F5B28BE6-8E8A-4F57-BA2E-9925D74E39E5 Q36783309-C5EC4911-B493-4CEA-AFF3-3D6866A7E86D Q36906022-A2333747-4558-47A0-BFC7-998762B7D597 Q37156611-C0E461AC-F178-44A8-BFB2-D76890FABB86 Q37507524-98D26447-6BE6-4371-A8F9-1D5634AEB79F Q37688355-7507A811-E6BE-47CB-B1AF-3074BA54C194 Q37833654-ADB92588-80E2-4D91-83EE-5C440FC5AACB Q38637914-8754B828-47E8-4B69-BA93-B9C94672699F Q38695896-C38DA91E-A986-4259-A8F9-2780A8CD1239 Q38707876-8F430EED-D351-4D06-BB2B-5713DE23948E Q38709544-B44C5E2F-33D4-4444-8F42-805A4330A0E1 Q38730539-9B730E66-36F6-4303-A31E-582BE8AD8735 Q38771703-455584E1-26E9-4D79-A898-757B7643EA86 Q38790957-29C76C3D-5C38-4FBB-A342-4EF27966EFDF Q38850598-E85B4B02-D77D-4477-AAA4-1D9C09A80929 Q38852455-3E037F17-D8B3-4822-9A75-4109263C9EC1 Q39024306-B70210FB-F364-4045-8FED-2B777F6321A0 Q39061630-8DAB2035-4BBF-4E13-860F-AE2D495FF4B8 Q39225738-9F3AA2F1-D074-4C06-B4C9-408C31FBB9ED Q39821089-45301CA4-E14C-4761-8CB1-CC59730CF88C Q41612803-BA0E3286-F6BA-46ED-8481-99D7F0EAB4F7 Q43400620-CEDC143D-4760-410A-9262-DDC773E12F20 Q47583420-3CF8BCC4-5760-482D-90C6-E93AAC41788A Q47750108-99222D80-F677-430A-B81F-8221CCC4A073 Q47956425-2D975EB5-7589-4176-8A96-05F4766FCF9D Q49523811-092AE079-C1EB-4D60-ABED-946CD49D1272 Q52598516-857C3DD4-1303-41F0-BAE1-C67BC3791469 Q52680700-78B72A6E-EBE7-4D7B-A701-7767B913090F Q53693522-6E39796C-262D-4B52-B58E-99114EE6B44E Q54111821-50EE00E5-329D-4C10-9D50-5D45BDB4AFD5 Q55098659-6213E58F-02DA-4F3A-B345-0BC3E92F42ED

P2860

Targeting BET bromodomains for cancer treatment

http://www.wikidata.org/entity/Q28263519

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Targeting BET bromodomains for cancer treatment

@ast

Targeting BET bromodomains for cancer treatment

@en

Targeting BET bromodomains for cancer treatment

@nl

type

label

Targeting BET bromodomains for cancer treatment

@ast

Targeting BET bromodomains for cancer treatment

@en

Targeting BET bromodomains for cancer treatment

@nl

prefLabel

Targeting BET bromodomains for cancer treatment

@ast

Targeting BET bromodomains for cancer treatment

@en

Targeting BET bromodomains for cancer treatment

@nl

P1433

Q28263519-9DAB7509-4F57-4E3B-937A-DB4030035E44

P1476

Q28263519-67736E58-221E-4E7C-94AC-71A0B052B9EF

P2093

Q28263519-4123E348-8718-4FFB-80B7-AE89C5697254

Q28263519-6EDA72FB-9C9E-48A6-B41D-4CC24248FA43

Q28263519-8C648D5C-B238-4690-9FE1-5A6253CF580F

Q28263519-E4BD3014-A89D-423F-8BD7-8B94C9A764B5

P2860

Q28263519-002327E4-E2C2-43D1-A86E-E10086655BE9

Q28263519-00D2B3DA-B611-4322-9EB8-9CD0D4BA686B

Q28263519-01C0ADB5-8452-4DC7-9173-39AC8835867F

Q28263519-06ADC536-93C8-4C40-BA56-B683EBC0E060

Q28263519-08F2AFE6-1815-44A7-AB31-D677EE0A19FA

Q28263519-0AC99F43-5E2E-4DCA-9DF4-5B2447C0AC4F

Q28263519-0CED5CB4-47AD-4C55-9BA0-4B048F654C3A

Q28263519-0FB3CDFF-0A93-4C7F-9511-298B8CFEE9BF

Q28263519-11971C1D-8937-41D9-B4E8-7131B7137CCE

Q28263519-11E36E07-D3EF-4381-87CB-582AE7DDBBBD

P304

Q28263519-7DCF225D-84E1-4BFB-997F-4F2AAB1C0432

P31

Q28263519-5A408A9E-B1EB-49F3-AD52-BBB9CC89389F

P3181

Q28263519-F11491E3-5EE6-4983-BD7B-3333492AE07A

P356

Q28263519-6BF08FDB-E38A-490D-8634-D2572D9FB783

P407

Q28263519-07E7053D-6A6E-44AD-917E-D65705F40830

P433

Q28263519-2CE19018-4B77-4592-9AFD-A8DEF0266878

P478

Q28263519-7011EE6E-B364-4518-9582-02C12386ADE9

P50

Q28263519-B467CA65-EB1E-48B1-952A-7D025696CF06

P577

Q28263519-D658DDF7-20B5-4E28-9D6A-1126135012E6

P698

Q28263519-E13260CE-F526-4B6F-A602-4487E5854DDB

P3181

P356

P1433

P1476

Targeting BET bromodomains for cancer treatment

@en

P2093

Bernard Haendler

http://www.w3.org/2001/XMLSchema#string

Kathy A Gelato

http://www.w3.org/2001/XMLSchema#string

Marie Jung

http://www.w3.org/2001/XMLSchema#string

Stephan Siegel

http://www.w3.org/2001/XMLSchema#string

P2860

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist

Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA

The bromodomain protein Brd4 insulates chromatin from DNA damage signalling

Selective inhibition of BET bromodomains

Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells

Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression

Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting

Histone recognition and large-scale structural analysis of the human bromodomain family

Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release

Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition

P304

487-501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1207033

http://www.w3.org/2001/XMLSchema#string

P356

10.2217/EPI.14.91

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Amaury E Fernández-Montalván

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26077433

http://www.w3.org/2001/XMLSchema#string